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Interleukin-12 (IL-12) has been inversely associated with disease severity in human and murine malaria, and
a polymorphism in the IL-12 p40 subunit gene (IL12B) has been associated with susceptibility to human
cerebral malaria and reduced nitric oxide (NO) production. To better define the relationships between IL-12,
NO, malaria parasitemia, and IL12B polymorphisms during malarial tolerance, plasma IL-12 levels and
peripheral blood mononuclear cell NO synthase (NOS) activity were measured in asymptomatic Papua New
Guineans exposed to intense malaria transmission. The IL-12 level was strongly inversely correlated with the
density of Plasmodium falciparum parasitemia (  0.45; P < 0.001) and was predicted to decrease by 19%
(95% confidence interval [CI], 10 to 27%) for each twofold increase in P. falciparum parasitemia. This is
consistent with a suppressive effect of parasitemia on IL-12 production, an effect previously shown in vitro and
in rodent models of disease. The IL-12 level was inversely correlated with NOS activity (r  0.22; P  0.007),
with each twofold increase in NOS activity being predictive of a 25% (95% CI, 7 to 38%) decrease in plasma
IL-12 levels. This probably reflects additional down-regulation of IL-12 by the high basal NO production and
monocyte NOS expression found in the malaria-tolerant state. Neither the IL-12 level nor NOS activity was
associated with either of two IL12B polymorphisms, reflecting the diversity of genetic control over immune
responses in different populations.
There is increasing recognition that interleukin-12 (IL-12)
plays an important regulatory role in both the cell-mediated (7,
8, 10, 11, 17–20) and antibody-mediated (21) immune re-
sponses to malaria. In murine malaria models, IL-12 adminis-
tration decreases mortality in association with a reduction in
peak parasitemia that appears to be critically dependent on
gamma interferon (IFN-) and partially dependent on nitric
oxide (NO) (19). In clinical studies, the plasma IL-12 level and
its ratio to that of anti-inflammatory mediators such as trans-
forming growth factor  (TGF-) have been inversely corre-
lated with disease severity (6, 10, 11, 17), although it has been
both positively (11) and negatively (10) correlated with Plas-
modium falciparum density. The relative contributions of ma-
laria parasitemia, other infections, cross-regulatory cytokines,
NO, and genetic determinants of IL-12 expression in the set-
ting of human malaria require further elucidation.
Innate and adaptive cell-mediated immune responses are
thought to be important in regulating “either the production or
downstream effects of endogenous pyrogens” (7) in individuals
from regions of highly endemic infection who are tolerant of
circulating malaria parasitemia, although the precise roles of
specific cytokines (including IL-12) are presently unknown.
Understanding the role of IL-12 and other mediators such as
NO in this setting is critical in fully informing the application of
novel immunopreventive and therapeutic strategies to popula-
tions living under conditions of intense malaria transmission.
We have previously defined two polymorphisms within IL12B,
the gene encoding the p40 subunit of IL-12. The point muta-
tion giving rise to the IL12B-3UTR polymorphism (designated
allele 1) was associated with higher IL-12 production and sus-
ceptibility to the autoimmune disorder type I diabetes (13),
whereas homozygosity for IL12B-pro allele 1 (an insertion al-
lele 4 bp longer than allele 2) was associated with increased
mortality from cerebral malaria and reduced NO production in
Tanzanian children (12). To our knowledge, the relationship
between IL-12 production and NO production and monocyte
NO synthase (NOS) activity has not been examined previously
in human malaria. In this study, we hypothesized that basal
IL-12 and NO production during good health in a population
chronically exposed to high-level malaria transmission would
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be positively correlated, in line with the general observation
that IL-12 is a potent stimulator of NO expression (16) and
with the association shown in our previous study (12). Further,
we hypothesized that IL-12 production would be increased in
subjects with an IL12B-pro allele 2 and/or and IL12B-3UTR
allele 1 and that both the presence and level of malaria para-
sitemia would be inversely correlated with IL-12 as previously
shown in clinical disease (7, 10).
MATERIALS AND METHODS
The subjects were coastal villagers from Madang, Papua New Guinea, where
malaria transmission is intense and all four parasite species infecting humans are
found (3). Informed consent was obtained in accordance with the ethical guide-
lines of the Human Research Ethics Committee of the Northern Territory
Department of Health and Community Services and Menzies School of Health
Research, Northern Territory, Australia, and the Papua New Guinea Medical
Research Advisory Committee.
Recruitment of study participants. Volunteers aged1 year were screened for
enrolment by a single blood smear between February and May 2000, with the aim
of positively selecting for parasitemic subjects in addition to recruiting negative
controls. Participants were excluded from the analysis if they were febrile (axil-
lary temperature, 37.5°C) on any of three occasions throughout a 24-h period,
had taken antimalarial or anti-inflammatory medication within 1 week, had
symptoms suggestive of recent (1 week) malaria infection (3), or had diarrhea
(since gastroenteritis may induce NO production). Subjects and controls were
fasted and supervised overnight for 12 h in their villages by a member of the
study team after a low-nitrate meal of chicken and rice to control for the
confounding effect of dietary nitrite and nitrate ingestion in quantitating NO
metabolites (1).
Specimen collection and assays. Venous blood was collected following the
fast, and a second blood smear was made (24 h after the first), plasma was
cryopreserved at 70°C, and peripheral blood mononuclear cells (PBMCs) were
separated by density gradient centrifugation. Thick and thin blood smears were
prepared with 4% Giemsa stain and examined by microscopists with 15 years
experience, and leukocyte counts were calculated manually for estimation of
parasitemia (3). Systemic NO production was determined by measuring the
concentration of nitrite plus nitrate (NOx) in urine and plasma by using Aspergil-
lus nitrate reductase coupled with the Griess reaction (1). NOS activity was
measured in PBMC pellet lysates by measuring the amount of [14C]arginine that
was converted to citrulline per milligram of total cellular protein per hour (23).
IL-12 levels were measured with a commercial sandwich enzyme-linked immu-
nosorbent assay kit (OptEIA; BD Pharmingen, San Diego, Calif.) as specified by
the manufacturer. The IL12B-pro and IL12B-3UTR genotypes were determined
by PCR and resolved on polyacrylamide gels as previously described (12).
Statistical analysis. The continuous variables plasma NOx, PBMC NOS ac-
tivity, IL-12 level, and P. falciparum parasite density were logarithmically trans-
formed for use in correlation analysis (testing Pearson’s r against 0 [and Spear-
man’s  against 0 for comparison to an earlier study; see Discussion]), multiple
linear-regression models, and Student’s t tests appropriate for variance. In sep-
arate models, P. falciparum density and IL-12 were transformed to log 2 purely
for explanatory purposes; this makes no difference to the interpretation of
statistical significance. The IL12B-pro and IL12B-3UTR polymorphisms were
considered in analysis of variance and linear-regression models categorized ac-
cording to separate genotypes (i.e., alleles 1-1, 1-2, and 2-2) and also according
to the following a priori hypotheses: for IL12B-pro, allele 1-1 versus 1-2 and 2-2
combined, and for IL12B-3UTR, allele 2-2 versus 1-1 and 1-2 combined. All
statistical analyses were performed using Stata 7.0 software (StataCorp), with P
values of 0.05 understood to indicate statistical significance. Since it was pre-
planned to make three pairwise comparisons in relation to the effect of para-
sitemia on IL-12 levels, consideration has been given in the discussion to how this
should be interpreted statistically.
RESULTS
Baseline characteristics. In the 424 villagers screened for
enrolment (median age, 16 years; interquartile range, 7 to 26
years), the prevalence of any malaria parasite was 45% and
that of P. falciparum was 30%. Plasma was available to test for
IL-12 in 161 enrolled subjects (median age, 15 years; IQR, 9 to
25 years), and PBMCs were collected and available for testing
in 142 subjects. The basic demographics and malaria status of
this cohort are shown in Table 1. No subjects were observed to
have breached the fasting protocol, and all were afebrile on up
to three occasions during a 24-h period. DNA amplification for
the IL12B-pro and IL12B-3UTR genotypes was successful in
157 and 154 subjects respectively. The number of subjects with
alleles 1-1, 1-2, and 2-2 was 110, 42, and 5, respectively, for
IL12B-pro and 33, 54, and 67, respectively, for IL12B-3UTR.
IL-12 levels and NO production. The geometric mean IL-12
in all subjects was 207 pg/ml (95% confidence interval [CI], 172
to 248 pg/ml), and there was no significant relationship be-
tween IL-12 and sex, age in years, or age when the patients
were put into groups aged 1 to 4, 5 to 9, 10 to 14, 15 to 19, and
20 years. IL-12 levels were significantly inversely correlated
with PBMC NOS activity (r 	0.22; P 	 0.007). Each twofold
increase in NOS activity was predictive of a 25% (95% CI, 7 to
38%) decrease in plasma IL-12 levels. There was no relation-
ship between IL-12 and plasma NO x level (P 	 0.99), and the
plasma NO x level was not correlated with PBMC NOS activity.
There were no significant relationships between IL-12, NOS
activity, or plasma NO x level and either of the IL12B poly-
morphisms, whether considered in three different allele cate-
gories or condensed to two as per the a priori hypothesis.
IL-12 levels and parasitemia. There was no difference in
IL-12 levels between subjects with any malaria parasitemia and
TABLE 1. Baseline characteristics of subjectsa
Age group
(yr)
Total no.
of patients
No. of patients negative
for parasitemia
No. (%) of patients
with parasitemiab
No. of patients with
P. falciparum includedc
P. falciparum
densityd
No. of patients infected withe:
P. falciparum
only
P. vivax
only Other
e
1–4 16 3 13 (81) 10 862 7 3 3
5–9 29 4 25 (86) 21 450 11 4 10
10–14 34 6 28 (82) 20 306 9 4 15
15–19 19 6 13 (68) 13 130 8 0 5
20 63 26 37 (59) 24 103 20 9 8
Totals 161 45 116 (72) 88 247 55 20 41
a The number of subjects with each type of malarial parasitemia is shown.
b The number and percentage of patients infected with any malaria parasite.
c Number of patients with P. falciparum included in the parasitemia.
d Geometric mean highest density of P. falciparum parasitemia from two consecutive daily blood smears (number of trophozoites per microliter).
e May include any combination of P. falciparum, P. vivax, P. malariae, and P. ovale.
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those who were aparasitemic (P 	 0.23) or between subjects
whose only parasitemia was due to P. falciparum and those who
were aparasitemic (P 	 0.35). However, the geometric mean
IL-12 was 31% (95% CI, 1 to 52%) lower in subjects with
parasitemia, including P. falciparum infection (175 pg/ml), than
in the combined group of aparasitemic subjects and subjects
infected with other Plasmodium species (252 pg/ml; P	 0.045).
Furthermore; P. falciparum density and IL-12 were strongly
inversely correlated (r 	 0.41;  	 0.45; P  0.001 for both
[Fig. 1]), with the IL-12 level predicted to decrease by 19%
(95% CI, 10 to 27%) for each twofold increase in P. falciparum
parasitemia. The statistical significance of the predictive effect
of NOS activity on IL-12 levels was reduced (P 	 0.09), but
that of P. falciparum density was not (P 	 0.001), when in-
cluded together in the regression model. Controlling for the
nonsignificant effect of age made no difference to the magni-
tude or significance of any of these relationships. Neither mea-
sure of NO production was significantly associated with ma-
laria parasitemia (data not shown).
DISCUSSION
This study has demonstrated a strong inverse correlation
between P. falciparum parasitemia and plasma IL-12 levels of
similar magnitude to that previously found in a study of un-
complicated and severe malaria cases (in which  was 0.51)
(10). The strength and direction of the relationship in this
study increases the validity of the finding that the IL-12 level
was also lower in subjects with P. falciparum parasitemia than
in those without (P 	 0.045), which was made in one of three
pairwise comparisons. This also supports the finding from a
previous study that background ex vivo IL-12 expression in
whole blood was associated with absence of parasitemia in an
asymptomatic malaria-exposed population (7), which was sig-
nificant but did not withstand statistical correction for multiple
comparisons.
There are a number of plausible explanations for these re-
sults that relate both to cause and effect. P. falciparum (22) and
P. yoelii (15) are known to directly suppress the secretion of
IL-12 by dendritic cells, and ingested malarial hemozoin has
been shown to impair mononuclear cell function (14). Indirect
suppression of IL-12 production may occur via induction of
IL-10 (25) and/or TGF-, cytokines proposed to explain the
lower production of IL-12 in severe malaria than in mild ma-
laria (17). Alternatively, although protozoan glycosylphos-
phatidylinositol molecules similar in structure to the proposed
glycosylphosphatidylinositol toxin of P. falciparum can induce
IL-12 production via binding to monocyte toll-like receptor 2
(5), repetitive stimulation may lead to down-regulation of
IL-12 in a process akin to endotoxin tolerance without neces-
sarily relying on IL-10 or other paracrine mediators (24). Since
IL-12 has been predominantly associated with antiparasitic
effects in murine malaria models (19), suppression of mono-
nuclear IL-12 production by P. falciparum in the malaria-tol-
erant state may allow greater parasite replication and higher
levels of parasitemia.
The inverse association between IL-12 production and
PBMC NOS activity that we have shown in the present study
was the opposite to what we expected, given that IL-12 is
generally thought to up-regulate NO (16); however, it is con-
sistent with the known inhibitory paracrine effect of NO on
IL-12 expression (9). Monocyte nitric oxide synthase 2 expres-
sion and NO production are known to be higher in the malaria-
tolerant state (2, 4), and in this setting NO may also contribute
to inhibition of IL-12 production.
The unexplained variance in plasma IL-12 levels in the
present study may be accounted for in part by interindividual
differences in the genes controlling IL-12 expression and/or
regulation. In another study (7), genetic differences were
thought more likely to explain the ex vivo correlation between
mitogen and P. falciparum antigen-stimulated whole-blood
IL-12 activity than was exposure to other infections, and a
polymorphism in the IL12B gene has been associated with
increased risk of death from cerebral malaria (12). On the
other hand, plasma IL-12 levels were lower in Gabonese chil-
dren with severe malaria than with mild malaria (10), but basal
levels in the same children after recovery were similar, which
argued against an important effect of host genetics. Increased
constitutive expression of IL-12 would be expected to be in-
versely associated with parasitemia if IL-12 is associated with
similar antiparasitic responses in murine and human malaria
(19). That plasma IL-12 levels and NO production were not
associated with either of the IL12B polymorphisms previously
associated with actual or predicted functional differences in
IL-12 expression (12) may not be surprising, given the geo-
graphical separation of the populations, the possibility that
linkage disequilibrium explained the earlier findings, and po-
tential differences in the background stimuli inducing NO and
IL-12. Additional studies involving in vitro stimulation of IL-12
response in individuals with different IL12B polymorphisms
may be necessary to determine their relevance to IL-12 pro-
duction in malaria-exposed populations.
Although the interrelationship between IL-12, other immu-
noregulatory cytokines, and malaria is complex, interpretation
of our data in the context of other studies (7, 10, 17) suggests
that IL-12 production is highest in asymptomatic malaria-ex-
posed subjects and then decreases in proportion to the level of
parasitemia, encompassing both the malaria-tolerant state and
FIG. 1. Relationship between plasma IL-12 level and P. falciparum
asexual parasite density. Individual values are represented by circles.
The straight line is the regression line showing a significant negative
inverse relationship (r2 	 0.17; P  0.001).
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clinical disease. If this interpretation is correct, the fact that
tolerance is necessarily lost in progressing from the asymptom-
atic to the diseased state provides further evidence that in-
creasing parasitemia causes lower levels of IL-12, rather than
low levels of IL-12 allowing higher parasitemias. Down-regu-
lation of monocyte IL-12 production (24) and constitutive fac-
tors may also determine IL-12 production during tolerance
(with a resultant effect on parasitemia, possibly via modulation
of IFN- production [18]), whereas different processes may be
operative during disease. While our findings suggest that high
levels of monocyte NOS activity and NO production found in
the tolerant state may contribute to the down-regulation of
IL-12 in malaria tolerance, it is unlikely to do so in clinical
disease, where both IL-12 (10, 17) and NOS2 (2) are similarly
suppressed in proportion to disease severity.
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